Phase I a study to evaluate GDC-6036 monotherapy in patients with non-small cell lung cancer (NSCLC) with KRAS G12C mutation
Authors
Sacher, A.Patel, M. R.
Miller, W. H.
Desai, J.
Garralda, E.
Bowyer, S.
Kim, T. W.
De Miguel, M.
Falcon, A.
Krebs, Matthew G
Lee, J.
Cheng, M.
Han, S. W.
Shacham-Shmueli, E.
Forster, M.
Jerusalem, G.
Massarelli, E.
Rodriguez, L. P. A.
Prenen, H.
Walpole, I.
Arbour, K.
Choi, Y.
Dharia, N. V.
Lin, M.
Mandlekar, S.
Joo, S. R.
Shi, Z.
Schutzman, J.
LoRusso, P.
Affiliation
Princess Margaret Cancer Center, TorontoIssue Date
2022
Metadata
Show full item recordCitation
Sacher A, Patel MR, Miller WH, Desai J, Garralda E, Bowyer S, et al. Phase I A Study to Evaluate GDC-6036 Monotherapy in Patients with Non-small Cell Lung Cancer (NSCLC) with KRAS G12C Mutation. Journal of Thoracic Oncology. 2022 Sep;17(9):S8-S9. PubMed PMID: WOS:000858678100014.Journal
Journal of Thoracic OncologyDOI
10.1016/j.jtho.2022.07.023Additional Links
https://dx.doi.org/10.1016/j.jtho.2022.07.023Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.jtho.2022.07.023